Investment to be utilized for scaling the company and commercialization of Qsant™, a urine test that monitors the health of transplanted kidneys PRESS RELEASE UPDATED: MAR 16, 2021 08:00 EDT SAN FRANCISCO, March 16, 2021 (Newswire.com) – NephroSant,…
Industry veteran to help support the company’s rapid growth as they launch their first test, QSant, a urine-based test for kidney transplant rejection. PRESS RELEASE UPDATED: FEB 16, 2021 SOUTH SAN FRANCISCO, Calif., February 16, 2021 (Newswire.com)…
SAN FRANCISCO, March 18, 2020 (Newswire.com) – NephroSant, a startup company that is focused on redefining kidney health, today announced the landmark publication showing high accuracy for a urine-based assay for the surveillance of kidney transplant patients…
